Table 3.
General features of laboratory (experimental) vaccine technologies
| Type | Type of modification | Production platform | Delivery method | Adjuvants | Dosage | Immunity provided | Safety |
|---|---|---|---|---|---|---|---|
| I. Inactivated | Physical, Chemical | Eukaryotic cell culture | Parenteral | Chemical | Repeated | Humoral and Th responses | +++ |
| II. Live Attenuated |
Physical Chemical mutagens, Reverse genetics, Tissue propagation (in vitro in vivo) |
Cell culture | Parenteral | none |
Single Repeated |
Humoral, and cellular including CTL responses | + |
| IIIa. Subunit & carrier technologies, glycoconjugate and peptide vaccines, microparticle and nanoparticle formulations, virus-like particles | Prokaryotic cell culture, Eukaryotic cell culture, Plant based. Chemical synthesis | Parenteral/mucosal | Chemical/Molecular | Repeated | Humoral and Th | ++++ | |
| IIIb. Nucleic acid | VpG, delivery, liposome | Prokaryotic cell culture | Parenteral | Molecular | Repeated | Humoral and cellular | +++ |
| IV. Viral Vector based | Mammalian, Insect, Plant cell culture | Parenteral | None/molecular |
Single Repeated |
Humoral and | +++ |